Building a Nordic company group.

 

Empowering research groups with state-of-the-art materials and
commercializing new clinical diagnostics.

 

Our mission

 

AlphaHelix group design, develop and distribute clinical and research products, both for the Nordic
and International markets. Our close relations with the research community enhance our capability
to monitor new diagnostic developments at an early stage; opening for partnerships on product
development, CE IVDR certification and commercialisation.

 

AlphaHelix Group

 

AlphaHelix Molecular Diagnostics (Publ.) is the holding company of the group owning patents
covering fast PCR-based amplification of purified and crude samples and a patent for fast and reliable
detection of CHD (Congenital Heart Defect) in fetuses. The company’s patented SuperConvection™
technology enables faster PCR/qPCR runs than any other technology on reaction volumes > 20 µl.
This unique ability combined with a patented method of handling crude samples opens possibilities
to detect viruses and bacteria’s without enrichment via cell culturing or DNA extractions within 30
minutes.

AlphaHelix Molecular Diagnostics is traded on Spotlight Stockmarket. The company has three
daughter companies, CyberGene, Techtum and AlphaHelix Technologies.

Qries

AlphaHelix Technologies develop and manufacture instruments used in diagnostics and PCR/qPCR. The company has currently one product,BugScreener™ is used for high throughput screening of MRSA (Methicillin Resistant Staphylococcus Aures) as well as other gastro intestinal bacteria’s. Over 2 million samples has been processed on BugScreener™ plattforms until now. BugScreener™ is currently not CE IVD certified, which exclude it from the European market.

Qries

Cybergene is a pioneer in QF-PCR for prenatal and male infertility diagnostics. The company is developing and manufacturing ChromoQuant® CE-IVD kits for the international market. CyberGene's QF-PCR technology has a number of advantages such as; significantly lower cost, faster turn-around- time, and higher confidence in the results. Products are distributed on an international market using local partners. Leveraging the market position and distributor network to expand into new diagnostics, focusing on the prenatal segment, is a key strategy for CyberGene

Qries

Techtum develop and manufacture instruments used in diagnostics and PCR/qPCR. The company has currently one product, BugScreener™ is used for high throughput screening of MRSA (Methicillin Resistant Staphylococcus Aures) as well as other gastro intestinal bacteria’s. Over 2 million samples has been processed on BugScreener™ plattforms until now. BugScreener™ is currently not CE IVD certified, which exclude it from the European market.

HEAD OFFICE

Västra Finnbodavägen 4B
SE-131 30 Nacka Stockholm
Sweden
+46 (0)862 67 600
sales@alphahelix.com

WAREHOUSE

Penarp 1150
SE-264 91 Klippan
Sweden
+46 (0)862 67 600
info@alphahelix.com
© 2017 AlphaHelix Technologies AB
Information om cookies